Orakl Oncology

Product

Orakl Oncology helps drug developers select cancer treatments and design clinical trials by combining laboratory tumour models with AI. The French company, a spin-off from Gustave Roussy, grows organoids from patients’ tumours, tests drug responses and links the results to clinical histories and molecular data.

Its O-Predict tools support response prediction, biomarker discovery and patient stratification. O-Target uses the same biological and computational foundation to identify potential therapeutic targets, giving pharmaceutical partners evidence for deciding which programmes to advance.